11/5/2026

speaker
Conference Operator
Operator

Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to the Terrasend Third Quarter 2026 Financial Results Conference Call. I will now turn the call over to Valter Pinto, Managing Director of KCSA Strategic Communications, for introductions. Please go ahead.

speaker
Valter Pinto
Managing Director, KCSA Strategic Communications

Thank you, operator, and good afternoon. Welcome to the Terrasend Third Quarter 2026 Financial Results Conference Call. Joining us for today's call is Jason Wild, Executive Chairman, Ziad Ghanem, President and Chief Executive Officer, and Eric Jackson, Chief Financial Officer. Our remarks today include forward-looking statements, including statements with respect to the company's outlook, including the company's expected financial results for the fourth quarter of 2026, and the estimates and assumptions relating thereto. The company's expectations regarding its growth prospects in new and existing markets, such as Ohio and New Jersey, its M&A strategy, including the expected contribution of the MRA's acquisition, The expansion of its cultivation capacity, the company's share repurchase program and capital allocation priorities, the company's plans regarding a potential uplisting to a U.S. exchange, and the expectations regarding regulatory reform, including rescheduling, potential tax relief and hemp regulation, and the potential benefits thereof. Each forward-looking statement discussed in today's call is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. The actual results and the timing of certain events may differ materially from the results or timing predicted or implied by such forward-looking statements, and reported results should not be considered as an indication of future performance. Additional information regarding these factors appears under the heading Risk Factors in the company's Form 10-K, filed with the Securities and Exchange Commission, and other filings that the company makes with the SEC from time to time, which are available at sec.gov, on CDAR+, and the company's website at terrasend.com. The forward-looking statements in this call speak as of today's date, and the company undertakes no obligation to update or revise any of these statements. Also during the call, the company may present both GAAP and non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is included in today's earnings press release and our quarterly report on Farm 10Q for the quarter ended September 30th, 2026, which you can find on the company's investor relations website or on the SEC and CDAR Plus websites. I'd now like to introduce Mr. Jason Wild. Please go ahead, Jason.

speaker
Jason Wild
Executive Chairman

Good afternoon, everyone, and thank you for joining us. Revenue, gross margin, EBITDA, and free cash flow for the third quarter increased year over year. Revenue totaled $68.2 million, a year-over-year increase of approximately 5%. Gross margin for the quarter was 52.3%, compared to 52.1% in the third quarter of 2025. Our adjusted EBITDA totaled $17.5 million compared to $17 million in the third quarter of 2025. We generated $8.8 million of net cash from operations and $6.1 million of free cash flow during the quarter, marking our 17th consecutive quarter of positive operating cash flow and 13th consecutive quarter of positive free cash flow, representing an impressive 17.7% operating cash flow yield and 14% free cash flow yield. These results reflect continued strength across our vertically integrated core markets of New Jersey, Maryland and Pennsylvania. In New Jersey, we closed on our previously announced transaction with Aunt Mary's, our fifth dispensary in the state, which generates over $10 million in annualized revenue and is immediately accretive on an EBITDA and free cash flow basis. We closed on Aunt Mary's in late September, and as a result, it only contributed marginally to revenue in the third quarter. In Maryland, we grew revenue both year over year and sequentially while maintaining strong margins. Pennsylvania, once again, was one of our strongest performing markets during the quarter, delivering substantial year over year revenue growth and margin expansion, driven by 12% same-store retail sales growth and a 31% increase in wholesale revenue. Turning to our balance sheet, we ended the quarter with $42.5 million in cash. Our continued free cash flow generation, strong balance sheet and our ability to access capital through our term loan facility provide us with the flexibility to act on additional attractive opportunities. We intend to put our capital to work through accretive, Acquisitions in markets where we already have scale and operational infrastructure, providing increased vertical revenue and further operating leverage. There are exciting opportunities in the market today and we look forward to providing an update on them in the coming weeks. Next, I want to provide an update on regulatory reform. As we have said before, we operate the business independent of regulatory reform and successful reform represents upside. The rescheduling of state-licensed medical cannabis to Schedule III earlier this year remains a monumental inflection point for our industry. The most immediate impact will be the elimination of the 280E tax burden on medical cannabis, which will materially improve profitability and cash flow generation, further strengthen our balance sheet, and lower our cost of capital over time. There also is the potential for retroactive tax relief, which could represent a significant upside opportunity that we do not believe is currently reflected in market valuations. We continue to report our results that include the impact of 280E and anticipate further updates in the fourth quarter. On the broader rescheduling of cannabis, the DEA administrative proceedings continue. While this process remains ongoing and the time and outcome remain uncertain, nothing we have seen changes our view on the eventual result. As part of the medical rescheduling process, the DEA has been conducting onsite inspections of our facilities. We have completed numerous inspections and the process is progressing. We also see continued progress on other important fronts. Enforcement against unregulated hemp products continues to build ahead of the intoxicating hemp ban scheduled to take effect on December 11th. As we have said before, the intoxicating hemp market is arguably our industry's largest competitor, and we look forward to serving those consumers as they return to the regulated market. We remain in active dialogue with the major U.S. exchanges and continue to take the necessary steps to prepare for a potential listing. On the M&A front, we are focused on disciplined, accretive acquisitions. As I mentioned, in September, we closed on end areas in New Jersey. The current environment continues to present opportunities, including distressed assets, both in our core markets and in select new markets. We have been patient and disciplined in these conversations, and I look forward to sharing an update in the coming weeks. Regarding our share repurchase program, In August, we renewed and replenished the authorization for up to the lesser of 10 million common shares or $10 million of common shares for the period beginning August 24th, 2026 through August 23rd of 2027. During the quarter, we had 35 trading days in our open trading window. During that period, we repurchased 1,013,000 shares. We will continue to execute on the buyback program while balancing other capital allocation priorities, including growth investments, capital expenditures, and selected M&A. With that, I will now turn the call over to Ziad to provide an update across our key markets.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Investor presentation